medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2008, Number 1

<< Back Next >>

Arch Neurocien 2008; 13 (1)

Analysis of cognitive decline in patients with huntington´s disease using unified huntington´s disease rating scale

Boll Marie-Catherine, Báez MEM, Ochoa A, Alonso ME

Language: Spanish
References: 16
Page: 25-30
PDF size: 94.63 Kb.


ABSTRACT

Previous to appearance of motor alterations in Huntington´s disease (HD), there can be a discreet cognitive deterioration. During the first decade of evolution of the disease, Mini-Mental State Examination and IQ test may be normal and application of highly sensitive tests become necessary in prediction of anomalies. The cognitive deterioration of HD subjects with less than 10 years evolution was studied using the tests of Verbal Fluency, Symbol Digit Modalities and the entire 3 parts of the Stroop test. A transversal analysis in 61 subjects was employed to seek for correlations of results in these tests and time of evolution of disease and motor deterioration. In the 52 subjects that finished every subsequent evaluation, rates of six-month, yearly and eighteen-month change were estimated. All cognitive tests were significantly related to the motor subscale and time of evolution. Correlation of results in the Stroop test with motor scale produced a Pearson’s correlation coefficient of -0.76 for word reading (part A), -0.68 for color naming (B) and -0.64 for interference test (C). Time of evolution was more highly related to the 2 remaining tests. The longitudinal study did not set in evidence any significant change with the exception of the quick reading section of Stroop A test, which showed 7 points deterioration in 18 months. This test turned out to be more sensitive than the other complex tasks for detection of any deterioration.


REFERENCES

  1. Riley BE, Orr HT. Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev 2006; 20: 2183-92.

  2. Mahant N, McCusker E.A., Byth K, Graham S. Huntington Study Group. Huntington´s disease. Clinical correlates of disability and progression. Neurology 2003;61:1085-92.

  3. Ross CA, Margolis RL, Rosenblatt A, Ranen NG, Becher MW, Aylward E. Huntington Disease and the Related Disorder, Dentatorubral – Pallidoluysian Atrophy (DRPLA). Medicine 1997;76:305-37.

  4. Fischer P. The spectrum of depressive pseudo-dementia. J Neural Transm Suppl 1996;47:193-203.

  5. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975;12:189-98.

  6. Hahn-Barma V, Deweer B, Durr A, et al. Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers.J Neurol Neurosurg Psychiatry 1998;64:172-7.

  7. Kirkwood SC, Siemers E, Stout JC et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol. 1999;56:563-8.

  8. Snowden JS, Craufurd D, Thompson J, Neary D. Psychomotor, executive, and memory function in preclinical Huntington’s disease. J Clin Exp Neuropsychol 2002; 24:133-45.

  9. Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Longitudinal evaluation of cognitive disorder in Huntington´s disease. J Int Neuropsychol Soc 2001; 7: 33-44.

  10. Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington´s disease is associated with striatal and insular atrophy: a neuropsychological and voxel – based morphometric study. J Neurol Sci 2005; 239:11-9.

  11. Huntington study group. Unified Huntington´s Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11:136-42.

  12. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington´s disease (HD) and asymptomatic carriers of the HD mutation. A longitudinal follow - up study. J Neurol 2004; 251:935-42.

  13. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington´s disease mutation after 1 year. Acta Neurol Scand 2002;106:131-41.

  14. Alonso ME, Yescas P, Cisneros B, et al. Analysis of the (CAG)n repeat causing Huntington´s disease in a Mexican population. Clin Genet 1997; 51: 225-30.

  15. Podoll K, Caspary P, Lange HW, et al. Language functions in Huntington´s disease. Brain 1988;111:1475-503

  16. Murray LL, Lenz LP. Productive syntax abilities in Huntington’s and Parkinson’s diseases. Brain Cogn 2001;46:213-9.




2020     |     www.medigraphic.com